The company said its Q4 2023 sales were $1.73 billion, up 6.5% from Q4 2022, operating income rose 12% to $445.0 million, and operating margin was 25.7%.

1. 01

   The company said its Q4 2023 sales were $1.73 billion, up 6.5% from Q4 2022, operating income rose 12% to $445.0 million, and operating margin was 25.7%.

2. 02

   The company said full-year sales for 2023 rose 7% to $6.60 billion, and operating income rose 14% to $1.71 billion. It said full-year GAAP diluted earnings per share were $5.67, and adjusted diluted earnings per share were $6.38.

3. 03

   The company said operating cash flow for Q4 2023 was $540.7 million, up 40% from the prior year. AMETEK's CEO said the company put about $2.25 billion of capital into acquisitions in 2023, and that the most recent was Paragon Medical.

4. 04

   The company said it expects sales for 2024 to rise low double digits on a percentage basis over 2023, and adjusted diluted earnings per share to be in the range of $6.70 to $6.85, an increase of 5% to 7%. It expects adjusted earnings per share for Q1 2024 of $1.56 to $1.60, up 5% to 7%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.